Unlocking NK Cell Therapy for Cancer
The past decade has seen meaningful advances in cell therapy for the treatment of cancer, with dramatic rates of clinical response in hematological malignancies and a rapid evolution of our understanding of factors that could extend this success to solid tumors. However, these therapies have been accompanied by severe and potentially life-threatening toxicities, and patient access is limited by complex, time-consuming, and costly patient-specific manufacturing. Cell therapy today is for the few, but we can do more.
Artiva Biotherapeutics is an oncology company with a “Manufacturing-First” strategy. We developed our AlloNKTM platform to advance highly scaled, off-the-shelf, allogeneic natural killer (NK) cell therapies for outpatient administration in the treatment of hematologic cancers and solid tumors. Our pipeline comprises both highly active non-genetically modified NK cell and CAR-NK cell therapies. Our non-genetically modified NK cells can be used as antibody-dependent cellular cytotoxicity (ADCC) enhancers in patients undergoing monoclonal antibody therapy. Our genetically modified CAR-NK cell therapies leverage the innate biology and safety features of NK cells, while enhancing their efficacy with chimeric antigen receptors (CARs). Artiva solves many of the previous challenges in cell therapy to deliver potentially life-saving treatments with safe, effective, scalable, versatile, and cost-effective NK cell products.